Search Results for "block"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for block. Results 71 to 73 of 73 total matches.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021 (Issue 1626)
maximum daily dose is reached (see Table 2).
Adverse Effects – ARBs, like ACE inhibitors, block ...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Drugs for Anxiety Disorders
The Medical Letter on Drugs and Therapeutics • Aug 07, 2023 (Issue 1682)
.
OTHER AGENTS — The sedating antidepressant
mirtazapine (Remeron, and others) blocks
presynaptic alpha2 ...
Anxiety disorders (generalized anxiety disorder,
panic disorder, social anxiety disorder, and various
phobias) are the most common form of psychiatric
illness. They can be treated effectively with cognitive
behavioral therapy (CBT) and/or pharmacotherapy.
Med Lett Drugs Ther. 2023 Aug 7;65(1682):121-8 doi:10.58347/tml.2023.1682a | Show Introduction Hide Introduction
Drugs for Depression
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023 (Issue 1691)
appetite, and hypertension. Dose-related seizures can occur.
MIRTAZAPINE — Mirtazapine blocks presynaptic ...
A selective serotonin reuptake inhibitor (SSRI) is
generally used for initial treatment of major depressive
disorder (MDD). A serotonin-norepinephrine reuptake
inhibitor (SNRI), bupropion (Wellbutrin SR, and
others), and mirtazapine (Remeron, and others) are
reasonable alternatives. Improvement in symptoms
can occur within the first two weeks of treatment
with these drugs, but a substantial benefit may not be
achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200 doi:10.58347/tml.2023.1691a | Show Introduction Hide Introduction